{"name":"Rhythm Pharmaceuticals","slug":"rhythm","ticker":"RYTM","exchange":"NASDAQ","domain":"rhythmtx.com","description":"Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next ge","hq":"Boston, MA","founded":2017,"employees":"414","ceo":"David Meeker","sector":"Rare Disease Biotech","stockPrice":87.03,"stockChange":0.37,"stockChangePercent":0.43,"marketCap":"$5.9B","metrics":{"revenue":189756992,"revenueGrowth":36.9,"grossMargin":89.7,"rdSpend":167340000,"netIncome":-196539000,"cash":388948992,"dividendYield":0,"peRatio":-234.3,"fiscalYear":"FY2018"},"revenueBreakdown":[],"timeline":[{"date":"2020-01-01","label":"Imcivree first approved","drug":"Imcivree","drugSlug":"setmelanotide","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"setmelanotide patent cliff ($0.0B at risk)","drug":"setmelanotide","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Imcivree","genericName":"SETMELANOTIDE","slug":"setmelanotide","indication":"BardetBiedl syndrome","status":"marketed"}]}],"pipeline":[{"name":"Imcivree","genericName":"SETMELANOTIDE","slug":"setmelanotide","phase":"marketed","mechanism":"Imcivree works by activating the melanocortin 4 receptor, a protein that helps regulate appetite and metabolism.","indications":["BardetBiedl syndrome","Leptin receptor (LEPR) deficiency","Obesity","Pro-opiomelanocortin (POMC) deficiency"],"catalyst":""}],"recentEvents":[{"date":"2023-05-04","type":"regulatory","headline":"Rhythm Pharmaceuticals Announces FDA Approval of Setmelanotide for the Treatment of Obesity and Other Conditions Associated with Leptin Receptor Deficiency","summary":"Rhythm Pharmaceuticals announced that the FDA has approved setmelanotide for the treatment of obesity and other conditions associated with leptin receptor deficiency.","drugName":"setmelanotide","sentiment":"positive"},{"date":"2022-02-24","type":"earnings","headline":"Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results","summary":"Rhythm Pharmaceuticals reported its fourth quarter and full year 2021 financial results, which included revenue of $13.4 million and a net loss of $44.8 million.","drugName":"","sentiment":"neutral"},{"date":"2021-12-06","type":"deal","headline":"Rhythm Pharmaceuticals Announces Collaboration with the National Institutes of Health to Develop New Treatments for Rare Genetic Disorders","summary":"Rhythm Pharmaceuticals announced a collaboration with the National Institutes of Health to develop new treatments for rare genetic disorders.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE5PSklkcXY5cW45V1Nxbm96bHNTX2FRQ2RXcnlON2ZseHNuUXVjaGNWbVBZVkN1Q0c4SjJyR3IxN25WYUpQOGRzMVJfZzlkUFpfZmc?oc=5","date":"2026-04-05","type":"pipeline","source":"Yahoo Finance UK","summary":"Rhythm Pharmaceuticals, Inc. (RYTM) stock price, news, quote and history - Yahoo Finance UK","headline":"Rhythm Pharmaceuticals, Inc. (RYTM) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQV3FCcTdHTmNHSzFXVkVTTE9sbU9OUXBWajB0d2JTc0g4TFZLekNtbHd4SElmcEpaZkJvZ1hXTU1TVURRelV5dW5QX1hnSUNubUstMWo3OFo0S2JqVEdjVUk4a1UyQlhqZXo1YWxhLVFqQlY5X3FBY2lOaW9nbE9WRHVrNXVoS1cybUdkVHVadlJFeXp4aWIxQ1h2YmV4NmtoMC1TYllNZHFyeE1lYTd2XzE3WHBNYmFwSVFXdzlhTUJNQzFkeVNJdkF3Yw?oc=5","date":"2026-04-03","type":"pipeline","source":"Stock Titan","summary":"Rhythm Pharmaceuticals (RYTM) director Kimberly Popovits files initial Form 3 - Stock Titan","headline":"Rhythm Pharmaceuticals (RYTM) director Kimberly Popovits files initial Form 3","sentiment":"neutral"},{"date":"2026-04-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxObkxHc3lCUy1CYm9fZFpvdERqVEhFZlY3cDZoWXZfNHd6RU9zTGppczJvUGlYWUVpclg1a3hMS05qVFBoNl9pSW9TeVR0NDJVZUNYOUFJU2luOU1Cemd3cGZDbFpvV0dnQlZHU3Y3TDFTOTdrVG5PZFliZE4xLUJjR3lJdUxvb3VpcGxYNjJlaw?oc=5","date":"2026-03-20","type":"regulatory","source":"Seeking Alpha","summary":"Rhythm Pharma higher after FDA label expansion for lead drug - Seeking Alpha","headline":"Rhythm Pharma higher after FDA label expansion for lead drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxORDRPSm9SS2JFUHd4LVFTOHdaRUI1YnN4SVRNQXRLYlBmak96NUNQeWMwZkhiUUJxTUdONlgyZ1p2elJMcHZoTEJjWkxoenBVcmJJT0RJbHdwQW1UQU5mbkJEcEhHRnJFdmRQeHdUemFtVjBXYVhLYWYtaGl4bFRDNFZNZTlNQklmZ0J3bXZOTjQyZ2d6bnZ3TU5IaFQ3S1ZrS2tSai1Zd0JzU3M4ZUZaOHRKX1ozSk5PT3lfcFhNWFhkSTB1cTlFZzlUNEQ3Vm54cXdWOC1XT0NtdWp5VzBqeGZCRG03VUdDMjRoYnFoUHB2cFlxcHhhVEtLMDg3Zm9zNVBvQVFmY2U?oc=5","date":"2026-03-20","type":"pipeline","source":"Finviz","summary":"PANTHERx Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE (setmelanotide) - Finviz","headline":"PANTHERx Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indicati","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgJBVV95cUxNUUUzWXg1NnBrN0dETXhNR3haNzBGOVJzRGlpS0RISGZWRDBTY1dOZE5CZVMxRF9jY2J2NXNoMEg5azUwczBCSlN1aS0tX3NmdWlPQV9EZV8tNkszZ0ttaERWNEtsaXRaTDVaSnIwbGFvcjNxbmc5Y0VvbnBYeHY3TEZiOEtfcThoelpETDhKbjlrdTFoUnVNRWZRSUFIa3VqRGk4MWh2TjNKVUZoUzRyR3hTT3VSMkQxVHNnSnR1TldxbXlnNXVKQXVVTnBqMlBUc3NZdnU4TEM1RWlZWU9LM0ZwZm1EU1F5Vzg4N1hkSlV6RXEzU0VKVFo0TUpmNkxWcUZHMTNBNTJoWlhrUVY2a2cxSmFzbTlVeG5CZ3FsZGkwZExmZkE?oc=5","date":"2026-03-20","type":"pipeline","source":"ChartMill","summary":"PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide) - ChartMill","headline":"PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indicat","sentiment":"neutral"},{"date":"2026-03-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOcm9UWmJQeWRsR1RLYWhyY3k4ZG8zLUNBUURhOXA0YnBiTmxZRXNuX25yODlneVFGZW50clQ5bXdJeFR1NFFBR1RaY28zbEx2Q3c2QWhHN2RsTjVMRHhSc3YwODBBRlFyZk5CYzB6bmNFMHh4X3dFS204RTZpRUQyS1JWdk8zZHA1TXBsa2o1bTVETDRTRzRMajZmLU9IcTZVQTVlLUxoZGREQ3BVX2V1QTZncmJ4T1E?oc=5","date":"2026-03-16","type":"trial","source":"Stock Titan","summary":"Obesity drug trial misses goal, yet some patients cut BMI by 9.7% - Stock Titan","headline":"Obesity drug trial misses goal, yet some patients cut BMI by 9.7%","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxORTlBcEtTRzNMM2NGSF9BbkQ4S0hMXzdtcDdJLU9zSVp6a3VuaVVDY0hHMEs4ZE04WndjOHB4QmhHUUthSk0wNTlvdk9TWHROenppeWY3LVdSaVFSaVluc283U0JFOW1WZThWSHk4MmNRY0RvWjl5T3ZfSHdlcUlCb1FoZGE2V05icDNibGVhVXpfc1BDeEVaRGZXY3FLeXRWZ1dBQ0ttN0N2OGU5M0V2emU3Zm5uTGstOWVGRQ?oc=5","date":"2026-03-16","type":"pipeline","source":"Stock Titan","summary":"Trust for Rhythm Pharmaceuticals (RYTM) director receives 4,199 shares - Stock Titan","headline":"Trust for Rhythm Pharmaceuticals (RYTM) director receives 4,199 shares","sentiment":"neutral"},{"date":"2026-03-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE5jeUU1WHhuTUtmaTAySG9lOHVmQ00tUnJtdnlFM0x3WVhzZFhoZUZQWnZBVEhscHg0azJua1BZQU5sSGNremNvQ1ctamZNNHNOUjQtS2RtZU9NMkZK?oc=5","date":"2025-12-29","type":"pipeline","source":"Finimize","summary":"Rhythm Pharma’s Rare-Obesity Drug Keeps Growth Rolling - Finimize","headline":"Rhythm Pharma’s Rare-Obesity Drug Keeps Growth Rolling","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxONFpMUWxMR1pFeGw5Wk43RlpHeWYxZjBjeVVhQ2xKTFVhQlVYR3E4dFFWVGl4djc1alMzUlRMLWRwdUg2aGdYTGZXdlpUN1JYYkVwVlZ3d0N2UUEwaUtWNmJyeHhsUXpPM25yQm5QQUloS3RrNWtNUXR4YXNPXzJrMXZuVzMwaWdwUG9TUUNrNGw5a3phNmg5WmNGTDdnWXJqRXpraUxB?oc=5","date":"2025-12-11","type":"pipeline","source":"Investor's Business Daily","summary":"Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win - Investor's Business Daily","headline":"Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win - Investor's Business Daily","sentiment":"neutral"}],"patents":[{"drugName":"setmelanotide","drugSlug":"setmelanotide","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Alexion Pharmaceuticals","BioMarin Pharmaceutical","Shire plc"],"therapeuticFocus":["Rare Genetic Disorders","Obesity"],"financials":{"source":"sec_edgar","revenue":0,"revenuePeriod":"2018-12-31","revenueHistory":[{"value":0,"period":"2018-12-31"},{"value":0,"period":"2017-12-31"},{"value":0,"period":"2017-12-31"},{"value":0,"period":"2016-12-31"},{"value":0,"period":"2016-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":167340000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-196539000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":480196000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":87.03,"previousClose":86.66,"fiftyTwoWeekHigh":122.2,"fiftyTwoWeekLow":49.86,"fiftyTwoWeekRange":"49.86 - 122.2","fiftyDayAverage":94.73,"twoHundredDayAverage":97.11,"beta":2.14,"enterpriseValue":5771763712,"forwardPE":-234.3,"priceToBook":42.06,"priceToSales":31.32,"enterpriseToRevenue":30.42,"enterpriseToEbitda":-30.27,"pegRatio":0,"ebitda":-190678000,"ebitdaMargin":-100.5,"freeCashflow":-145983376,"operatingCashflow":-115675000,"totalDebt":112174000,"debtToEquity":41.5,"currentRatio":4.41,"returnOnAssets":-27.5,"returnOnEquity":-90.5,"analystRating":"1.4 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":15,"targetMeanPrice":137.67,"targetHighPrice":158,"targetLowPrice":105,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.8,"institutionHeldPercent":108.9,"sharesOutstanding":68285039,"floatShares":55449500,"sharesShort":6535847,"shortRatio":7.97,"shortPercentOfFloat":9.6,"epsTrailing":-3.11,"epsForward":-0.37,"revenuePerShare":2.92,"bookValue":2.07,"officers":[{"age":71,"name":"Dr. David P. Meeker M.D.","title":"Chairman, President & CEO"},{"age":56,"name":"Mr. Hunter C. Smith M.B.A.","title":"CFO & Treasurer"},{"age":50,"name":"Mr. Joseph  Shulman","title":"Chief Technical Officer"},{"age":52,"name":"Mr. Yann  Mazabraud","title":"Executive VP & Head of International"},{"age":50,"name":"Ms. Jennifer  Lee","title":"Executive VP & Head of North America"},{"age":54,"name":"Mr. Christopher P. German","title":"Corporate Controller & Principal Accounting Officer"},{"age":45,"name":"Dr. Alastair  Garfield Ph.D.","title":"Chief Scientific Officer"},{"age":null,"name":"Mr. David  Connolly","title":"Head of Investor Relations & Corporate Communications"}],"industry":"Biotechnology","irWebsite":"","website":"https://rhythmtx.com","phone":"857 264 4280"}}